Pfizer-Allergan A Go Despite New Tax Inversion Rules?

By | November 20, 2015

Scalper1 News

As expected, the Treasury Department late Thursday issued tougher rules governing tax inversions, where a U.S. company buys an overseas firm and then moves its headquarters to that country to get more favorable tax treatment. It wasn’t clear immediately how the new rules might impact a possible Pfizer (PFE) acquisition of Ireland-based Allergan (AGN), a deal valued at up to $157 billion. Pfizer and Allergan shares edged higher in late trading Scalper1 News

Scalper1 News